VUmc Cancer Center Amsterdam / VUmc Institute for Cancer & Immunology CCA/V-ICI
|
|
- Georgina Pierce
- 8 years ago
- Views:
Transcription
1 VUmc Cancer Center Amsterdam / VUmc Institute for Cancer & Immunology CCA/V-ICI Annual Report 2010
2 Address VUmc Cancer Center Amsterdam / VUmc Institute for Cancer & Immunology (CCA/V-ICI) VU University Medical Center CCA 3.36 De Boelelaan HV Amsterdam The Netherlands phone: (31) v-ici@vumc.nl website : 1
3 2
4 List of contents List of contents 1. Preface 5 2. Description of CCA/V-ICI 7 3. Structure of CCA/V-ICI 9 4. SWOT analysis International collaboration Input CCA/V-ICI Output CCA/V-ICI The research programs of CCA/V-ICI Scientific Research Committee Training and education 47 Appendices 53 3
5 4
6 1. Preface 1. Preface It is a great pleasure to present the 2010 annual report of CCA/V-ICI. The institute is really flourishing with an even rising production in scientific output, both quantitatively and qualitatively. In 2010, some important steps were made: the foci in patient care of VUmc: "zwaartepunten", were further defined. For CCA/V-ICI cancer and immunology in patient care go side by side with the researchprograms and further integration of care and research are very rapidly progressing. I wish you much pleasure in reading this report! Peter Huijgens, director 5
7 6
8 2. Description of CCA/V-ICI 2. Description of CCA/V-ICI CCA/V-ICI is one of the five research institutes of the VU University Medical Center. CCA/V-ICI was created to integrate all research efforts in oncology and immunology in such a way that they strengthen themselves to reach well-defined, interconnected goals. Furthermore, CCA/V-ICI aims to create new facilities for fundamental and clinical research, both in terms of laboratory facilities, and technical equipment, and will stimulate cooperation. CCA/V-ICI is positioned horizontally in the structure of the VUMC, thus interfacing with the different divisions of clinical and pre-clinical departments. The CCA/V-ICI organization is built around the top researchers in oncology and immunology in the VUMC. They are the members of the executive board, advising the management board that heads the institute. A detailed description of the organization of CCA/V-ICI, together with the organization scheme is given in appendix 1. About 75% of all VUmc medical departments are involved in research focussed on oncology and/or immunology. Research is conducted within five well defined research themes. Furthermore, five tumour types and two immunological disorders have been selected to form the focus for ongoing research efforts during virtually every stage of the disease. These include colorectal cancer, lung cancer, head and neck cancer, haematological cancers, neuro-oncology, rheumatoid disease, coeliakie, contact dermatitis and inflammatory bowel disease. In these patient groups, comprehensive clinical and research programmes will be established in which clinical care and research are fully integrated. These range from early detection and diagnosis to treatment and palliative care. Furthermore, CCA/V-ICI has excellent research expertise on HPV-related tumors, esophagus cancer, prostate cancer, retinoblastomas,breast cancer, psoriasis, insulin allergy and autoimmune hepatitis. To ensure that all the clinicians and researchers within CCA/V-ICI remain highly qualified, a lifelong learning programme has been set up, starting with undergraduate (bio)medical students and continuing through Master s and PhD level to postgraduate/specialist training and beyond. Mission The mission of CCA/V-ICI is to coordinate, stimulate and facilitate: - top level fundamental, translational and patient related research in immunology and cancer, within the framework of a defined number of research themes - top level multidisciplinary patient care - creation of excellent facilities for research and patient care - training of (young) investigators to ensure excellent fundamental and clinical researchers - optimal training of health care workers - fundraising To this end the tasks of CCA/V-ICI are: - Development of long-term policy - Attuning the institutional policy and the policies of the participating (heads of) departments - Facilitation and coordination of oncology and immunology research - Quality control and stimulation of research by stimulating cross interfaces between departments, research groups and clusters - Training, supervision and assessment of graduate students in research - Organization of courses, national and international seminars, entrance examinations, publications, conferences and all that is necessary in this frame work - Facilitation of multidisciplinary patient care and early diagnosis - Facilitation of providing information to patients and their relatives - Facilitation of the development of cure/care pathways for oncological and immunological patients groups - Facilitation of research facilities - Quality control and stimulation of support systems for clinical research - Training of health care workers; a.o. in the medical curriculum, and post-academic education - Coordination of the funding of programs 7
9 2. Description of CCA/V-ICI CCA/V-ICI future plans CCA/V-ICI aims to take and hold a leading position in fundamental and patient related research in cancer and immunology and to improve curative and palliative patient care and to be an attractive partner for external partners. In particular CCA/V-ICI will focus on: Virus-induced oncogenesis and the role of cancer genes in frequently occurring sporadic and inherited tumors Development of cell based immunotherapy against cancer and new immunosuppressive methods in immunological diseases Classification of diseases and disease monitoring by molecular imaging, genomics and proteomics Introduction and evaluation of new therapeutic modalities, combining immunotherapeutical approaches, DNA technology and improving existing therapy methods Translational research: what benefit will the aforementioned focus points bring for the patients. Generation of improved knowledge about quality of life of childhood and adult patients with oncological and immune-mediated diseases and their families and conduction of high quality innovative translational research into developments and readily available new supportive care strategies. 8
10 3. Structure of CCA/V-ICI 3. Structure of CCA/V-ICI The research projects in CCA/V-ICI are grouped in programs headed by three to five program leaders who are responsible for the organization, the coordination and the quality of the program. The program leaders constitute the Executive Board of CCA/V-ICI that reports to the Management Board of CCA/V-ICI. Program 1: Oncogenesis Program 1 covers both basic and translational research and is divided into two subthemes: 1. Viral oncogenesis, progression and early diagnostics 2. Genetic predisposition and cancer genes Program 2: Immunopathogenesis The CCA/V-ICI program 2 covers both fundamental and pre-clinical research in which immunological processes underlying homeostasis control, in relation with inflammatory diseases and cancer form major topics of research. Program 2 is subdivided into three research lines: 1. Homeostasis control and Inflammation 2. Host-pathogen interaction 3. Tumor immunology and pre-clinical immune therapy Program 3: Disease profiling The CCA/V-ICI program 3 covers fundamental and translational research to identify new determinants for diagnosis, prognosis and tailored treatment for immunological and oncological diseases. Program 3 is subdivided in three disease oriented research lines: 1. Solid tumors 2. Hematological malignancies 3. Chronic inflammatory diseases Program 4: Innovative therapy The CCA/V-ICI program 4 encompasses translational research within the field of oncological and immune-mediated, non-oncological diseases. The program has been organized along four research lines: 1. Chemotherapy 2. Immunotherapy 3. Radiotherapy and surgery 4. Gene therapy Program 5: Quality of life The CCA/V-ICI program 5 encompasses research within the field of quality of life of childhood and adult patients with oncological and immune-mediated, non-oncological diseases. The program Quality of life addresses four main topics: 1. Patient and proxy reported outcome 2. Allied health services and lifestyle 3. Psycho-oncology 4. Palliative Care 9
11 10
12 4. SWOT analysis 4. SWOT analysis Strengths: Strong clinical and fundamental research units in one institute with excellent translational research lines Excellent facilities Excellent teaching program, including strong masterprograms Flat organization, theme meetings and general meetings Coordinated project applications Outpatient facility Strong departments represented in all crucial committees A number of exceptional strong clinical departments nationwide and worldwide (Pathology, Otolaryngology/Head-Neck Surgery, Hematology, Medical Oncology) Weakness: Dispersion in therapy program Limited equipment budget Strong dependence of translational research on patient mix Opportunities: Development of more bench to bedside research lines Integration of immunological and cancer research to develop new immunotherapeutical approaches New imaging facility Cooperation with other research institutes in Amsterdam and the western part of the Netherlands Threats: Financial situation of university medical centers in the Netherlands Increasing focusing of VUMC towards patient care because of financial reasons 11
13 12
14 5. International collaboration 5. International collaboration Investigator Prominent associates Ang CW K.A. Krogfelt, Statens Serum Institut, Copenhagen, Denmark Appelmelk BJ J. Nigou, Centre National de la Recherche Scientifique, Département, Mécanismes Moléculaires des Infections Mycobacteriennes, Institut de Pharmacologie et de Biologie Structurale, and Institut de Pharmacologie et de Biologie Structurale, Université detoulouse, Université Paul Sabatier (Toulouse III), Toulouse, France G. Besra, School of Biosciences, University of Birmingham, Edgbaston, United Kingdom D. Umetsu, Harvard Medical School, Boston, USA Beelen RHJ J. Loreiro/M. Lopez Cabrera, Insituto de Biologica, Moleculas Eladio Vinuela, Madrid, Spain M. Bohm/C. Aufricht, Medizinische Universitaet, Pediatric and Adolescent Medicine, Vienna, Austria P. Fabbrini, Instito Renal Medicine, Milan, Italy Bitter W Richard Losick, Harvard University, Cambridge, USA Boers M Prof P. Tugwell, Prof G. Wells, University of Ottawa, Ca Prof D. Felson, University of Boston, USA Prof P. Brooks, University of Brisbane, Australia Prof V. Strand, University of Stanford, USA Prof. J. Kirwan, University of Bristol, UK Prof, W. Maksymovich, University of Edmonton, Canada Prof. J. Blazenby, University of Bristol, UK Dr. R. Christensen, University of Copenhagen, Denmark Braakhuis BJM Dr P. Golusinsky, Poznan University of Medical Sciences, Poznan, Poland Brakenhoff RH Prof A Ferlito, Dept Surgical Sciences, University of Udine, Italy Prof F McCormick, Director Cancer Centre UCSF, USA Dr N Korokhov, Vector Logics Inc, Birmignham AL, USA Castelijns JA P. Galluzzi, A.Cerasi, Department of Neurosciences, Azienda Ospedaliera Universitaria Senese, Interdepartmental Center of Nuclear Magnetic Resonance, University of Siena, Siena, Italy. Gizewski ER, Forsting M, Department of Diagnostic and Interventional Neuroradiology, University Hospital, Essen, Germany. Brisse HJ, Department of Radiology, Institute Curie, Paris, France Maeder P, Pediatric Hematology Oncology Unit and Radiology Department Service de radiodiagnostic et de radiologie interventionnelle CHUV Centre Hospitalier Universitaire Vaudois University Hospital CHUV, Lausanne, Switzerland Cloos J A.D. Schimmer, Princess Margaret Hospital, Ontario Cancer Institute, Toronto, Canada de Gruijl TD Dr C.H. June, Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Philadelphia, USA Dr D.T. Curiel, Division of human gene therapy, University of Alabama at Birmingham, Birmingham Alabama, USA de Winter JP Krystyna H. Chrzanowska, Department of Medical Genetics, The Children s Memorial Health Institute, Warsaw, Poland Weidong Wang, National Institute on Aging, Baltimore, USA Dorsman JC Antoine M. Snijders, Cancer Research Institute, Comprehensive Cancer, University of California, San Francisco, CA, USA Gibbs S Sens-it-iv consortium (30 international partners multiple publications), Multiple in Europe ( Europe Giovannetti E Prof. F. De Braud, European Institute of Oncology, Milano, Italy Prof. U. Boggi, University of Pisa, Italy Prof. Daniela Campani, Associate Professor of Pathology, University of Pisa, Pisa, Italy Prof. Federico Cappuzzo, head dept. Oncology, Livorno Civil Hospital, Carrara, Italy 13
15 5. International collaboration Investigator Prominent associates Prof. Armando Santoro, head dept. Oncology and Hematology, Humanitas Hospital, Milan, Italy Prof. A. Falcone, Dept. Oncology, University of Pisa, Pisa, Italy Prof. R. Rosell, Dept. Oncology, Barcelona, Spain Dr. F. Crea, Scuola di Studi Superiori S.Anna, Pisa, Italy Dr. M. Cantore, Dept. Oncology, Civic Hospital Carrara, Carrara, Italy Dr. Marco del Chiaro, Karolinska Institute, Stockholm, Sweden Dr. Leticia G Leon, Instituto Universitario de Bio-Organica Antonio Gonzalez (IUBO-AG), C/Astrofísico Francisco Sanchez Universidad de La Laguna, La Laguna, Spain R. Danesi, University of Pisa, Pisa, Italy Prof. Giuseppe Giaccone, Chief Medicine Oncology Branch, National Cancer Institute, Bethesda, USA. Dr. P.A. Zucali & Prof. Dr. A Santoro, Humanitas Hospital, Milan, Italy Prof Filippo Minutolo, Associate Professor of Medicinal Chemistry, University of Pisa, Pisa, Italy Dr. Carmelo Tibaldi, University of Livorno, Livorno, Italy Dr. N Funel, University of Pisa, Pisa, Italy Prof. Dr. Y. Assaraf, Technion-Israel, Institute of Technology University, Haifa, Israel Heideman DAM Dr. S. Franceschi, International Agency Research on Cancer (IARC), Lyon, France Dr. G. Clifford, International Agency Research on Cancer (IARC), Lyon, France Dr. R. Thomas and colleagues, Max Planck Institute for Neurological Research, Klaus-Joachim-Zülch Laboratories of the Max Planck Society and the Medical Faculty of the University of Cologne, Cologne, Germany European Early Lung cancer (EUELC) Consortium: John K. Field, Roy Castle Lung Cancer Research Programme, Cancer Research Centre, University of Liverpool, Liverpool, United Kingdom; Christian Brambilla, Institut Albert Bonniot, Université Joseph Fourier, INSERM U823; Grenoble, France Jansen G Prof dr. Y.G. Assaraf, The Technion-Israel Institute of Technology, Haifa, Israel Jiménez C, Schaaij-Visser TB, Pham TV, Piersma SR, Wurdinger T, Peerdeman SM, Saydam O, and Stemmer-Rachamimov AO O. Senol, Harvard Medical School, Boston, USA Kirtschig G Prof. Dr. H Williams, Nottingham University, Nottingham, UK EADV task force Skin disease in pregnancy, EADV, last meeting at the EADV event in Gotheburg, Sweden Mebius R Meijer GA Ronen Alon, the Weizmann Institute of Science, Rehovot, Israel Steven Pals, AMC, dept Pathology, Amsterdam A.J. Habenicht, Institute for Vascular Medicine, Friedrich Schiller University of Jena, Germany Prof. E. Schröck, Institut für Klinische Genetik, Medizinische Fakultät Carl Gustav Carus der TU Dresden, Dresden, Germany Prof. J.G. Herman and Prof. S. Bayling, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA Prof. F Pontén, Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden Prof. P. Quirke and H. Grabsch, PhD, Academic Unit of Pathology, University of Leeds, United Kingdom Prof. D. Sidransky,The Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America Prof. W. van Criekinge, OncoMethylome Sciences S.A, Liege, Belgium R.T. Cormier, University of Minnesota Medical School, Duluth, MN, USA Prof. G.Giaccone, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA K.H. Buetow PhD, Center for Biomedical Informatics and Information Technology National Cancer Institute, Bethesda, MD, USA Mooi WJ Prof. R.L. Barnhill, Université Paris VII, France Prof. M. Cook, Nuffield Health Guildhford Hospital, England Prof. L. Cerroni, University of Graz, Austria Prof. D.E. Elder, University of Pennsylvania, USA Prof. H. Kerl, University of Graz, Austria Prof. P.E. LeBoit, University of San Francisco, USA Prof M. Mihm, Harvard University, USA 14
16 5. International collaboration Investigator Prominent associates Prof. R. Scolyer, University of Sydney, Australia Prof. L. Cerroni, University of Sydney, Australia Prof. L. Cerroni, University of Graz, Austria Peters GJ Dr. R.A. Schwendener, University of Zürich, Zürich, Switserland Prof. Dr. H Schott, University of Tubingen, Tubingen, Germany prof. Dr. J Balzarini, Rega Instituut, KU Leuven, Leuven, Belgium Prof. Dr. O Fodstadt, Radium Hospital, Oslo, Norway Prof. Dr. S. Eriksson, Uppsala University, Uppsala, Sweden Dr. M. Sandvold, Clavis Pharma ASA, Oslo, Norway C. Calhau, University of Porto, Porto, Portugal I. Fichtner, Max-Delbrück-Center for Molecular Medicine, Berlin-Buch, Germany. Dr. J.M. Padron, Instituto Canario de Investigación del Cáncer (ICIC), Tenerife, Spain Dr. M Fukushima, Taiho Pharmacenticals, Tokushima, Japan Prof.dr. H. Schott, University of Tubingen, Germany Dr. C.M. Galmarini, PharmaMar, Madrid, Spain Prof. Alfredo Falcone, Head Department of Oncology, University of Pisa, Pisa, Italy Prof. Ugo Boggi, Full Professor of Surgery, University of Pisa, Pisa, Italy Prof. Daniela Campani, Associate Professor of Pathology, University of Pisa, Pisa, Italy Prof. Federico Cappuzzo, Head Department of Oncology, Livorno Civil Hospital, Livorno, Italy Dr. Maurizio Cantore, Head Department of Oncology, Carrara Civic Hospital, Carrara, Italy Prof. Filippo De Braud, Head Unit Oncology and New Drugs, European Institute of Oncology, Milan, Italy Dr. Marco Del Chiaro, Karolinska Institute, Stockholm, Sweden Dr. Leticia G Leon, Instituto Universitario de Bio-Organica Antonio Gonzalez (IUBO-AG), C/Astrofísico Francisco Sanchez Universidad de La Laguna, La Laguna, Spain R. Danesi, University of Pisa, Pisa, Italy Prof. Giuseppe Giaccone, Chief Medicine Oncology Branch, National Cancer Institute, Bethesda, USA. Dr. P.A. Zucali & Prof. Dr. A Santoro, Humanitas Hospital, Milan, Italy Prof Filippo Minutolo, Associate Professor of Medicinal Chemistry, University of Pisa, Pisa, Italy Dr. Carmelo Tibaldi, University of Livorno, Livorno, Italy Dr. N Funel, University of Pisa, Pisa, Italy Prof. Dr. Y. Assaraf, Technion-Israel, Institute of Technology University, Haifa, Israel Rustemeyer T Sens-it-iv consortium (30 international partners 1 publication), Multiple in Europe ( Europe Savelkoul PHM Nuno Pais, Roche Molecular Systems, Plesangton, USA Senan S D. Palma, London Regional Cancer Program, Ontario, Canada Kong (Spring) FM, University of Michigan Medical School; Ann Arbor, Michigan W.D. D Souza, University of Maryland School of Medicine, Baltimore, USA C. le Péchoux, Institut Gustave Roussy, Paris, France J.P. van Meerbeeck, University of Ghent, Ghent, Belgium G. Scagliotti, University of Turin, San Luigi Hospital, Turin, Italy U Nestle, Freiburg University Medical Center, Freiburg, Germany C. Faivre-Finn, The Christie, Manchester, United Kingdom S. Ishikura, National Cancer Center Hospital East, Kashiwa, Japan Slotman BJ D. Palma, London Regional Cancer Program, Ontario, Canada Sminia P Fedrigo C.A. Catholic University Rio Grande do Sul, Porte Alegro, Rio Grande do Sul, Brazil van Beusechem VW Prof. F. McCormick, UCSF Cancer Center, San Francisco, California, USA Dr. Z.B. Zhu, Gene Therapy Center, UAB, Birmingham, Alabama, USA van de Loosdrecht AA Dr. S.M. van Ham, Sanquin Research at CLB, Amsterdam Dr. T. van den Berg, Sanquin Research at CLB, Amsterdam Prof. Dr S. Ostrand-Rosenberg; Baltimore, USA Dr. M. Loken and D. Wells. HematoLogics Inc. Seattle USA 15
17 5. International collaboration Investigator Prominent associates European LeukemiaNet MDS working package 8 (implemanatation of flowcytometry in MDS) Dr. J. Janssen, Prof.dr. T. de Witte. UMCN, Nijmegen Dr. M. Raaijmakers, ErasmusMC, Rotterdam van den Elsen PJ K Kobayashi, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA M Villalba, Institut de Génétique Moléculaire de Montpellier, Unité Mixte de Recherche 5535, Centre National de Recherche Scientifique, Montpellier, France J. McClusky, Department of Microbiology & Immunology, The University of Melbourne, Parkville, Victoria 3010, Australia van der Horst-Bruinsma IE ASAS- Society: internationaal samenwerkingsverband van reumatologen mbt spondylitis ankylopoetica van der Sar AM Dr. S. Bird, University of Aberdeen, Aberdeen, UK van der Waal I Meleti M, Unit of Oral Pathology and Medicine, Section of Odontostomatology, Department of ENT/Dental/Ophthalmological and Cervico-Facial Sciences, University of Parma, Italy R.A. Mendes, Department of Oral Surgery, Faculty of Dental Medicine, University of Porto, Porto, Portugal J.F.C. Carvalho, Department of Oral Surgery, Faculty of Dental Medicine, University of Porto, Porto, Portugal R.A. Mendes, Instituto Superior de Ciências da Saúde, Norte, Porto, Portugal. G. Warfvinge, Department of Pathology, Malmö, Sweden van Die I R. Geyer, Giessen University, Germany R.D. Cummings, Emory University Medical School, Atlanta, USA van Dongen GAMS Kiefer GE, Jurek P, Macrocyclics Inc, Dallas, Texas, USA van Egmond M Prof.dr. P. Kubes, University of Calgary, Calgary, Canada Prof.dr. J. Ivanyi, Kings College, London, UK van Furth AM Prof. dr. J. Schoeman, Tijgerberg Hospital, Cape Town, South-Africa van Furth AM and van der Kuip M Prof. D. Kirschner, Department of Microbiology and Immunology, Uiversity of Michigan, Ann Arbor, Michigan, USA van Kooyk Y Collaboration with the group of Dr. Eduardo Arranz (Mucosal Immunology Lab, Dept. of Paediatrics & Immunology-IBGM, University of Valladolid, Valladolid, Spain) on immunomodulation of gliadin-specific immune responses through C-type lectin receptor targeting. Resulted in the visit of a PhD student (Enrique Montalvillo) for two months (October-November, 2010) Verweij CL Prof. dr. P.h. De Jager, Harvard University, Boston, USA Prof. Dr. D.A. Hafler, Yale University, Rochester, USA Prof. dr. M. Holers/ Dr. K. Dean, University of Colorado, Denver, USA Prof. dr. M. Comabella/Prof. dr. X. Montalban,, University of Vall d Hebron,, Barcelona, Spain Wurdinger T Dr. Bakhos Tannous, Massachusetts General Hospital/Harvard Medical School, Boston/USA Ylstra B Prof. dr. Nick Gilbert, Univeristy of Edinburgh, Edinburgh, UK Prof. dr. Patricia Maciel, University Minho, Portugal Zweegman S M.Huizing, Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA 16
18 6. Input CCA/V-ICI 6. Input CCA/V-ICI a. Acquisition per type of funding in euros Funding Direct funding Research funding Contracts Total As percentage: Funding Direct funding 51,3% 51,3% 50,3% 59,9% Research funding 13,3% 12,9% 12,6% 11,5% Contracts 35,4% 35,8% 37,1% 28,6% Total 100% 100,0% 100,0% 100,0% b. Fte per type of funding For a full list of all scientific input, see appendix 2. Total fte (including PhD students) Program WP1 Fte WP2 fte WP3 fte WP4 fte Total fte 1. Oncogenesis 13,97 5,13 22,62 3,17 44,89 2. Immunopathogenesis 21,61 24,55 16,33 3,67 66,16 3. Disease profiling 15,78 5,50 14,85 5,50 41,63 4. Innovative therapy 23,89 2,89 27,84 13,40 68,02 5. Quality of life 2,2 1,51 3,24 2,42 9,37 Total ,45 39,58 84,88 28,16 230,07 Total staff ,63 37,32 80,53 24,22 212,70 Total staff ,31 34,90 65,21 19,58 188,00 Total staff ,24 28,60 55,78 18,91 178,53 17
19 6. Input CCA/V-ICI Total fte PhD students Program WP1 Fte WP2 fte WP3 fte WP4 fte Total fte 1. Oncogenesis 3,42 2,10 11,30 1,50 18,32 2. Immunopathogenesis 7,85 7,71 6,80 2,25 24,61 3. Disease profiling 6,38 2,30 9,15 3,90 21,73 4. Innovative therapy 4,40 1,81 18,10 7,61 31,92 5. Quality of life 0,95 0,61 2,24 1,42 5,22 Total ,00 14,53 47,59 16,68 101,80 Total ,24 14,40 44,41 15,79 94,84 Total ,69 23,87 16,16 29,25 79,97 Total ,55 21,45 16,79 29,25 81,04 Total fte (including PhD students) program 1 program 2 program 3 program 4 program WP1 WP2 WP3 WP4 c. Number of all newly started PhD projects in 2010 In 2010, 19 new PhD projects were started. For a full list of all newly started projects and PhD students, see appendix 3. 18
20 7. Output CCA/V-ICI 7. Output CCA/V-ICI a. Scientific output A full list of the scientific output can be found in appendix 4. Program WpR WpNR WP VP PP OCT DI 1. Oncogenesis Immunopathogenesis Disease profiling Therapy Quality of life Total * Total Total Total WpR: Scientific papers refereed (former WI, WN + LE) WpNR: Scientific papers non refereed (former WI*) WP: Scientific publications (book, book chapters, proceedings) (former WB, WBC, RA) VP: Professional publications PP: Popular publications OCT: Patents DI: Dissertations *Due to an intense search on the internet, the amount of scientific papers are significantly higher than the years before. b. Scientific quality Evaluation of peer-reviewed publications (Science Citation Index (SCI) journals) Program A B C D 1. Oncogenesis ,9 73,5 2. Immunopathogenesis ,0 72,7 3. Disease profiling ,0 72,3 4. Therapy ,9 69,9 5. Quality of life ,7 60,6 Total ,9 70,6 Total ,9 70,3 Total ,8 67,6 Total ,8 62,1 Relation between scores and journal 5: SCI journal belonging to > 90th percentile (5 points) 4: SCI journal belonging to 75th 90th percentile (4 points) 3: SCI journal belonging to 50th - 75th percentile (3 points) 2: SCI journal belonging to 25th 50th percentile (2 points) 1: SCI journal from lowest quarter, publications in peer-reviewed journals without an Impact Factor (1 point) 19
21 7. Output CCA/V-ICI A: WI total B: Total points C: Average points D: Percentage of WI SCI journals in upper quartile (4 + 5) c. Indicators of esteem An overview of editorships, memberships, invited lectures, awards, grants obtained, organisation of congresses and news are outlined in appendix 5. d. Societal impact An overview of the Societal Impact of CCA/V-ICI is shown in appendix 6. e. Input/Output correlation Program Total fte Total WpR Average WpR/fte 2010 Average WpR/fte 2009 Average WpR/fte 2008 Average WpR/fte Oncogenesis 44, ,1 1,0 1,3 1,6 2. Immunopathogenesis 66, ,9 2,7 2,2 2,3 3. Disease profiling 41, ,0 2,6 4,1 2,3 4. Innovative therapy 68, ,9 2,6 2,2 2,7 5. Quality of life 9, ,5 6,4 - - Total 230, ,7 2,5 2,5 2,4 20
22 8. The research programs of CCA/V-ICI 8. The research programs of CCA/V-ICI A long-term policy is developed for the programs, covering their focus, the need for personnel and materials, their budgets and their development. These long-term plans constitute the basis of the long-term policy of CCA/V-ICI. Research projects are evaluated on their (intrinsic) qualities and on their potential to strengthen the program as a whole. The program leaders present such projects in the EB for advice upon which the Management Board decides to allow or not to allow the project into CCA/V-ICI. A list of all ongoing projects per program is shown in appendix 7. a. Description Program 1: Oncogenesis Program leaders: - Prof. R.H. Brakenhoff, PhD (Otolaryngology/Head-Neck Surgery) - Prof. H. Joenje, PhD (Clinical Genetics) - Prof. P.J.F. Snijders, PhD (Pathology) Program 1 covers both basic and translational research and is divided into three subthemes: 1. Viral oncogenesis 2. Cancer genomics 3. Genetic predisposition A major common objective of the research brought together in this program is to identify and characterize viral and non-viral cancer genes as well as genes responsible for inherited cancer predisposition. Their roles in oncogenic pathways are evaluated in models and clinical material. In addition, molecular markers are sought that may be utilized for a) screening for cancer and precancerous lesions, b) risk assessment of precancerous lesions, and c) cancer prevention. To this end an integrated bench to bedside approach is followed encompassing: 1) marker identification and clinical validation, 2) test development, validation and up-scaling by robotics, 3) risk group identification, 4) cost-effectiveness modelling, and 5) public acceptance studies. Screening studies are running for oral precancer, colorectal cancer and cervical cancer, in various risk groups, and often in the context of population-based screening trials. 1. Viral oncogenesis This subtheme focuses on the role of human papillomaviruses (HPVs) and Epstein Barr virus (EBV) in the development of human cancers, such as anogenital cancers, head and neck cancers, and lymphomas. Virus-induced oncogenic progression is investigated using both in vitro models and clinically well-defined patient material, and the genes involved in this process are identified and characterized. Viral and host markers are already being tested in screening and clinical trials for their capability to assess the risk of premalignant disease with an increased sensitivity and specificity compared to currently existing methods, and newly identified markers will be investigated likewise. 2. Cancer genomics Aimed at testing progression models for several human cancers, such as head and neck, lung, gastrointestinal, cervical and ovarian cancers, this subtheme uses wellcharacterized cohorts of patients and state-of-the art high-throughput methods for genetic, epigenetic, transcriptome and proteome analyses. Candidate cancer genes are identified, placed in their respective cancer pathways, and tested for their oncogenic capacity with the aid of in vitro models. Promising progression markers are evaluated in clinical studies. 3. Genetic predisposition In this subtheme understanding the molecular mechanisms of genome destabilization, as related to the occurrence of cancer, both familial and sporadic is studied. Attention is currently focusing on Fanconi anemia (FA), for which the pathway is being unravelled (13 FA genes known to date) and mouse models are being developed. It is recognized 21
INSERM/ A. Bernheim. Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance
A. Bernheim Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance OVER-MyR is funded by the European Commission within its FP7 specific
More informationImmuno-Oncology Therapies to Treat Lung Cancer
Immuno-Oncology Therapies to Treat Lung Cancer What you need to know ONCHQ14NP07519 Introduction: Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body s own
More informationSommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle
Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle TITLE PROJET NOM HOPITAL Assessment of tumor angiogenesis using PET/CT with 18 F-Galacto- RGD. (PNC_29_001) Division of
More informationOncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder
Oncos Therapeutics: Personalized Cancer Immunotherapy ONCOS THERAPEUTICS Personalized Cancer Immunotherapy March 2015 Antti Vuolanto, COO and co-founder 1 History of Oncos Therapeutics 2002 2007 2009 Research
More informationReport from the visiting commitee
Section des Unités de recherche Report from the visiting commitee Research unit: Biothérapies hépatiques University of Nantes January 2008 Section des Unités de recherche Report from the visiting committee
More informationA Genetic Analysis of Rheumatoid Arthritis
A Genetic Analysis of Rheumatoid Arthritis Introduction to Rheumatoid Arthritis: Classification and Diagnosis Rheumatoid arthritis is a chronic inflammatory disorder that affects mainly synovial joints.
More informationAutoimmunity and immunemediated. FOCiS. Lecture outline
1 Autoimmunity and immunemediated inflammatory diseases Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline Pathogenesis of autoimmunity: why selftolerance fails Genetics of autoimmune diseases Therapeutic
More informationScientific Programme
Scientific Programme Scientific Committee Hilary Calvert UCL Cancer Institute, London, UK Luca Gianni Ospedale San Raffaele IRCCS, Milan, Italy Ana Maria Gonzalez-Angulo Cristiana Sessa Istituto Oncologico
More informationThe role of IBV proteins in protection: cellular immune responses. COST meeting WG2 + WG3 Budapest, Hungary, 2015
The role of IBV proteins in protection: cellular immune responses COST meeting WG2 + WG3 Budapest, Hungary, 2015 1 Presentation include: Laboratory results Literature summary Role of T cells in response
More informationPh.D. in Molecular Medicine
Ph.D. in Molecular Medicine and Translational Research College of Medicine 1. Introduction: The College of Medicine, while consolidating on its undergraduate innovative educational programs, decided to
More informationGene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press
Gene Therapy The use of DNA as a drug Edited by Gavin Brooks BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Contents Preface xiii Acknowledgements xv About the editor xvi Contributors xvii An introduction
More informationA Career in Pediatric Hematology-Oncology? Think About It...
A Career in Pediatric Hematology-Oncology? Think About It... What does a pediatric hematologist-oncologist do? What kind of training is necessary? Is there a future need for specialists in this area? T
More informationCourse Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry
Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry The Master Degree in Medical Laboratory Sciences /Clinical Biochemistry, is awarded by the Faculty of Graduate Studies
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationVUmc Cancer Center Amsterdam / VUmc Institute for Cancer & Immunology CCA/V-ICI
VUmc Cancer Center Amsterdam / VUmc Institute for Cancer & Immunology CCA/V-ICI Annual Report 2009 Address VUmc Cancer Center Amsterdam / VUmc Institute for Cancer & Immunology (CCA/V-ICI) VU University
More information1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1
1 page Overview 21 Oct Tuesday 1500 on REGISTRATION 1800 Welcome Reception & Cocktails at the Cape Town International Conference Centre (CTICC) 22 Oct Wednesday 0730 REGISTRATION 0830 OPENING 0900 PLENARY
More informationTHE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER AT JOHNS HOPKINS
Ushering in a new era of cancer medicine Center is ushering in a new era of cancer medicine. Progress that could not even be imagined a decade ago is now being realized in our laboratories and our clinics.
More informationThe immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor
The immune system Basophil Neutrophil Bone marrow Eosinophil Myeloid progenitor Dendritic cell Pluripotent Stem cell Lymphoid progenitor Platelets Bone marrow Thymus NK cell T-cell B-cell Spleen Cancer
More informationGroundbreaking Collaborative Clinical Trial Launched
Groundbreaking Collaborative Clinical Trial Launched For immediate release Media Contacts: June 16, 2014 Richard Folkers Alison Hendrie 9:00 a.m., EDT Foundation for the NIH Rubenstein Communications (301)
More informationspecific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins
Adaptive Immunity Chapter 17: Adaptive (specific) Immunity Bio 139 Dr. Amy Rogers Host defenses that are specific to a particular infectious agent Can be innate or genetic for humans as a group: most microbes
More informationCourse Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology
Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology The Master Degree in Medical Laboratory Sciences / Clinical Microbiology, Immunology or
More information7- Doctoral Degree in Public Health and Public Health Sciences (Majoring Microbiology)
7- Doctoral Degree in Public Health and Public Health Sciences (Majoring Microbiology) Students should fulfill a total of 44 credit hours: 1- Compulsory courses: 14 credit hours. 1504801, 1504802, 1504803,
More informationReport series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
More informationFulfilling the Promise
Fulfilling the Promise Advancing the Fight Against Cancer: America s Medical Schools and Teaching Hospitals For more than a century, the nation s medical schools and teaching hospitals have worked to understand,
More informationLCFA/IASLC LORI MONROE SCHOLARSHIP IN TRANSLATIONAL LUNG CANCER RESEARCH
LCFA/IASLC LORI MONROE SCHOLARSHIP IN TRANSLATIONAL LUNG CANCER RESEARCH FUNDING OPPORTUNITY DESCRIPTION 2016 REQUEST FOR APPLICATION (RFA) Lung Cancer Foundation of America (LCFA) and the International
More informationOutline. Predictive Assays in Radiation Therapy Immunotherapy in Cancer Treatment. Introduction. Current clinical practice
Predictive Assays in Radiation Therapy Immunotherapy in Cancer Treatment Radiation Biology Outline Introduction: Predictive assays in radiation therapy Examples for specific tumors Immunotherapy Summary
More informationFACULTY OF ALLIED HEALTH SCIENCES
FACULTY OF ALLIED HEALTH SCIENCES 102 Naresuan University FACULTY OF ALLIED HEALTH SCIENCES has focused on providing strong professional programs, including Medical established as one of the leading institutes
More informationITT Advanced Medical Technologies - A Programmer's Overview
ITT Advanced Medical Technologies (Ileri Tip Teknolojileri) ITT Advanced Medical Technologies (Ileri Tip Teknolojileri) is a biotechnology company (SME) established in Turkey. Its activity area is research,
More informationTransgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO
Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Statistically significant difference in progression-free survival continues to be seen in non-squamous
More informationELCC 2015 Industry Satellite Symposium The Treatment Roadmap for Squamous NSCLC. Thursday 16th April 2015 13:10 14:20 Room C
ELCC 2015 Industry Satellite Symposium The Treatment Roadmap for Squamous NSCLC Thursday 16th April 2015 13:10 14:20 Room C 1 Contents Programme.... 2 Welcome message.... 3 Faculty biographies.... 4 Symposium
More information1150 W. Medical Center Dr. Research Investigator Ann Arbor, MI 48109 Department of Microbiology and Immunology phone: (734)763-5364
Alteri, Christopher J. 5641 Medical Science Bldg. II 1150 W. Medical Center Dr. Research Investigator Ann Arbor, MI 48109 Department of Microbiology and Immunology phone: (734)763-5364 University of Michigan
More informationEMBL. International PhD Training. Mikko Taipale, PhD Whitehead Institute/MIT Cambridge, MA USA
EMBL International PhD Training Mikko Taipale, PhD Whitehead Institute/MIT Cambridge, MA USA Why create an EMBL? The structure of DNA had been solved and first protein structures were being identified
More informationVUmc Cancer Center Amsterdam / VUmc Institute for Cancer & Immunology CCA/V-ICI
VUmc Cancer Center Amsterdam / VUmc Institute for Cancer & Immunology CCA/V-ICI Annual Report 2007 Address VUmc Cancer Center Amsterdam / VUmc Institute for Cancer & Immunology (CCA/V-ICI) VU University
More informationNew Investigators. 2012 report
New Investigators 2012 report Summary Cancer Research UK has a strong portfolio of fellowships to support new researchers at the start of their independent careers. We currently support our new investigators
More informationCONTRACTING ORGANIZATION: University of Alabama at Birmingham Birmingham, AL 35294
AD Award Number: W81XWH-08-1-0030 TITLE: Regulation of Prostate Cancer Bone Metastasis by DKK1 PRINCIPAL INVESTIGATOR: Gregory A. Clines, M.D., Ph.D. CONTRACTING ORGANIZATION: University of Alabama at
More information30-31. Advancesincancer immunologyand immunotherapy. announcement. October2015. Royal Olympic Hotel Athens
Advancesincancer immunologyand immunotherapy 30-31 October2015 Royal Olympic Hotel Athens announcement Organizer Hellenic Oncology Research Group (HORG) Symposium chairs N. Kentepozidis, A. Kotsakis, M.
More informationFuture Oncology: Technology, Products, Market and Service Opportunities
Brochure More information from http://www.researchandmarkets.com/reports/296370/ Future Oncology: Technology, Products, Market and Service Opportunities Description: Future Oncology is an analytical newsletter
More informationThe Biological Basis of Cancer. Annie Young, Professor of Nursing, University of Warwick, University Hospitals Coventry and Warwickshire
The Biological Basis of Cancer Annie Young, Professor of Nursing, University of Warwick, University Hospitals Coventry and Warwickshire Aim of Presentation By the end of this presentation you will: Be
More informationOne out of every two men and one out of every three women will have some type of cancer at some point during their lifetime. 3
1. What is cancer? 2. What causes cancer?. What causes cancer? 3. Can cancer be prevented? The Facts One out of every two men and one out of every three women will have some type of cancer at some point
More informationALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES
ALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES DESCRIPTION OF GRANT MECHANISM The Alliance for Lupus Research (ALR) is an independent,
More informationTargeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma
The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.
More informationFASEB Directory of Members Online
Head, Department of Anatomy and Radiology The College of Veterinary Medicine at the University of Georgia invites nominations and applications for the position of Head of the Department of Anatomy and
More informationSummary of Discussion on Non-clinical Pharmacology Studies on Anticancer Drugs
Provisional Translation (as of January 27, 2014)* November 15, 2013 Pharmaceuticals and Bio-products Subcommittees, Science Board Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer
More informationVUmc Cancer Center Amsterdam / VUmc Institute for Cancer & Immunology CCA/V-ICI
VUmc Cancer Center Amsterdam / VUmc Institute for Cancer & Immunology CCA/V-ICI Annual Report 2008 Address VUmc Cancer Center Amsterdam / VUmc Institute for Cancer & Immunology (CCA/V-ICI) VU University
More informationTHE LINCOLN INSTITUTE OF HEALTH
THE LINCOLN INSTITUTE OF HEALTH Background The Chair in the Care of the Older Person will be part of the new Lincoln Institute of Health, a cross disciplinary research collaboration linking schools, colleges
More informationFACULTY OF MEDICAL SCIENCE
Doctor of Philosophy Program in Microbiology FACULTY OF MEDICAL SCIENCE Naresuan University 171 Doctor of Philosophy Program in Microbiology The time is critical now for graduate education and research
More informationCourse Descriptions. I. Professional Courses: MSEG 7216: Introduction to Infectious Diseases (Medical Students)
Course Descriptions I. Professional Courses: MSEG 7216: Introduction to Infectious Diseases (Medical Students) This course is offered during the first semester of the second year of the MD Program. It
More informationFuture Directions in Cancer Research What does is mean for medical physicists and AAPM?
Future Directions in Cancer Research What does is mean for medical physicists and AAPM? John D. Hazle, Ph.D., FAAPM, FACR President-elect American Association of Physicists in Medicine Professor and Chairman
More informationNEW HYBRID IMAGING TECHNOLOGY MAY HAVE BIG POTENTIAL FOR IMPROVING DIAGNOSIS OF PROSTATE CANCER
Media Release April 7, 2009 For Immediate Release NEW HYBRID IMAGING TECHNOLOGY MAY HAVE BIG POTENTIAL FOR IMPROVING DIAGNOSIS OF PROSTATE CANCER London, Ontario Improved hybrid imaging techniques developed
More information2 Year (2013 15) CLL/SLL Research Initiative CLL/SLL Collaborative Grant
2 Year (2013 15) CLL/SLL Research Initiative CLL/SLL Collaborative Grant Guidelines & General Instructions for Application KEY DATES: Application Release Date: December 12, 2012 Application Deadline: February
More informationDr Alexander Henzing
Horizon 2020 Health, Demographic Change & Wellbeing EU funding, research and collaboration opportunities for 2016/17 Innovate UK funding opportunities in omics, bridging health and life sciences Dr Alexander
More informationCore Topic 2. The immune system and how vaccines work
Core Topic 2 The immune system and how vaccines work Learning outcome To be able to describe in outline the immune system and how vaccines work in individuals and populations Learning objectives Explain
More informationTABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending...
CANCER TABLE OF CONTENTS Introduction...1 Chapter1 AdvancesinTreatment...2 Chapter2 MedicinesinDevelopment......11 Chapter3 ValueandSpending......15 Chapter4 Conclusion...22 INTRODUCTION Researchers and
More information1) Siderophores are bacterial proteins that compete with animal A) Antibodies. B) Red blood cells. C) Transferrin. D) White blood cells. E) Receptors.
Prof. Lester s BIOL 210 Practice Exam 4 (There is no answer key. Please do not email or ask me for answers.) Chapters 15, 16, 17, 19, HIV/AIDS, TB, Quorum Sensing 1) Siderophores are bacterial proteins
More informationMaster of Physician Assistant Studies Course Descriptions for Year I
FALL TERM COURSES: Master of Physician Assistant Studies Course Descriptions for Year I PHAC 7230 Fundamentals in Pharmacology for Health Care I Credit Hrs: 3 This course will build on foundational knowledge
More informationCAREERS IN BIOMEDICAL SCIENCE & THE IBMS. Betty Kyle Scottish Regional Representative IBMS Lead Biomedical Scientist NHS Lanarkshire
CAREERS IN BIOMEDICAL SCIENCE & THE IBMS Betty Kyle Scottish Regional Representative IBMS Lead Biomedical Scientist NHS Lanarkshire What is a biomedical scientist? Biomedical scientists carry out investigations
More informationFORM ENTRY INSTRUCTIONS FOR THE RESEARCH SEMINARS AND EVENTS WEB PAGE
FORM ENTRY INSTRUCTIONS FOR THE RESEARCH SEMINARS AND EVENTS WEB PAGE ABOUT THE RESEARCH SEMINARS AND EVENTS WEB PAGE The RESEARCH SEMINARS AND EVENTS web page was created to provide a one stop internet
More informationThe Features of World-Class Universities
The Features of World-Class ersities Hsiou-Hsia Tai Professor, Institute of Education Associate Dean, College of Humanities and Social Sciences National Chiao Tung ersity Hsin-chu, Taiwan Introduction
More informationWhat is Cancer? Cancer is a genetic disease: Cancer typically involves a change in gene expression/function:
Cancer is a genetic disease: Inherited cancer Sporadic cancer What is Cancer? Cancer typically involves a change in gene expression/function: Qualitative change Quantitative change Any cancer causing genetic
More informationCNIO Frontiers Meetings Molecular Cancer Therapeutics Madrid, March 8 10, 2010
CNIO Frontiers Meetings Molecular Cancer Therapeutics Madrid, March 8 10, 2010 Organisers S. Gail Eckhardt, University of Colorado Denver, Aurora, USA Roy S. Herbst, The University of Texas MD Anderson
More informationUnderstanding the Molecular and Cellular Biology of Endocrine-Related Cancers. Mont Ste. Odile, Alsace, France 11-14 September 2008
33 rd European Symposium on Hormones and Cell Regulation Understanding the Molecular and Cellular Biology of Endocrine-Related Cancers Mont Ste. Odile, Alsace, France 11-14 September 2008 Invited Speakers:
More informationNew Directions in Treatment of Ovarian Cancer. Amit M. Oza Princess Margaret Hospital University of Toronto
New Directions in Treatment of Ovarian Cancer Amit M. Oza Princess Margaret Hospital University of Toronto Newly diagnosed: scenario Ist line Surgery chemotherapy Cure If can t cure can we turn into chronic
More informationThe Pre-Medical Program. Start your career in medicine at University College Roosevelt. www.ucr.nl
The Pre-Medical Program Start your career in medicine at University College Roosevelt www.ucr.nl University College Roosevelt Pre-Medical Program University College Roosevelt (UCR) is the international
More informationHow To Choose A Pediatric Oncologist
Dr. Geoff Cuvelier MD FRCPC Pediatric Oncologist Dr. Cuvelier is a graduate of the Faculty of Medicine, University of Manitoba, and received undergraduate degrees in microbiology and sociology from the
More informationMaster Online Study Program @dvanced Oncology. Study part time team up internationally!
Master Online Study Program @dvanced Oncology Study part time team up internationally! Ulm University is developing an innovative international postgraduate study program @dvanced Oncology addressing clinical
More informationNEW ALLIANCE FOR EUROPEAN EXCELLENCE AND COMPETITIVENESS IN LIFE SCIENCES
PRESS RELEASE NEW ALLIANCE FOR EUROPEAN EXCELLENCE AND COMPETITIVENESS IN LIFE SCIENCES European research centres in life sciences gather to foster excellence in research, share knowledge, and influence
More informationPhD Education at Erasmus MC
PhD Education at Erasmus MC Research training in biomedical, clinical and health sciences Rita Struhkamp, Department of Research Policy FAQ s Where to start? Brochure Erasmus MC Graduate School www.erasmusmc.nl/phd
More informationONCOLOGY NURSING 7 TH ESO-EONS MASTERCLASS IN. 8-13 March 2014 Ermatingen (Lake Constance) Switzerland MASTERCLASS
MASTERCLASS Photo: Turm by Stephan Balkenhol - A Sculpture for Wolfsberg Photographer: Ralph Feiner, Architekturfotografie, Malans 7 TH ESO-EONS MASTERCLASS IN ONCOLOGY NURSING 8-13 March 2014 Ermatingen
More informationHow To Learn More About Melanoma
PROGRAMMA SCIENTIFICO MELANOMA BRIDGE 2012, DECEMBER 2 ND -4 TH 2012 Presidents: Paolo A. Ascierto, Francesco M. Marincola and Nicola Mozzillo Scientific Board Paolo A. Ascierto Gennaro Ciliberto Bernard
More informationBIOSCIENCES COURSE TITLE AWARD
COURSE TITLE AWARD BIOSCIENCES As a Biosciences undergraduate student at the University of Westminster, you will benefit from some of the best teaching and facilities available. Our courses combine lecture,
More informationU.S. News Best Global Universities Rankings: An inside look at the latest results and methodology
U.S. News Best Global Universities Rankings: An inside look at the latest results and methodology Robert J. Morse, Chief Data Strategist U.S. News & World Report 6th International Conference on World-Class
More informationRegional Young Investigator SIC meeting. 5-6 March 2015
Regional Young Investigator SIC meeting 5-6 March 2015 Aula Magna A - Università Magna Graecia di Catanzaro - Campus Universitario S. Venuta Viale Europa, loc. Germaneto - Catanzaro Invited speakers: Rita
More informationIndependent Validation of the Prognostic Gene Expression Ratio Test in Formalin Fixed, Paraffin Embedded (FFPE) Mesothelioma Tumor Tissue Specimens
Independent Validation of the Prognostic Gene Expression Ratio Test in Formalin Fixed, Paraffin Embedded (FFPE) Mesothelioma Tumor Tissue Specimens Assunta De Rienzo, Ph.D. 1, Robert W. Cook, Ph.D. 2,
More informationProspects for Vaccines against Hepatitis C Viruses. T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS
Prospects for Vaccines against Hepatitis C Viruses T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS HCV Vaccine Prevention strategies Protective immunity Barriers and solutions Vaccine candidates
More informationFrom Immunotherapy of Cancer to the Discovery of Kidney Cancer Genes
ISSN 2154-4006 The Genetic Basis of Human Disease zbar Colloquium series on Series Editor: Michael Dean, Ph.D., Head, Human Genetics Section, Senior Investigator, Laboratory of Experimental Immunology
More informationProgramme. Michele Grieco Dipartimento di Scienze Ambientali Seconda Università degli Studi di Napoli Naples, Italy
Programme Invited Speakers: Reuven Agami (The Netherlands), Manuela Baccarini (Austria), Allan Balmain (USA), Daniel Birnbaum (France), Anne-Lise Børresen-Dale (Norway), Carlos Caldas (UK), Silvana Canevari
More informationNuevas tecnologías basadas en biomarcadores para oncología
Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS
More informationMaster of Science in Biochemistry (Molecular Medicine Option).
Master of Science in Biochemistry (Molecular Medicine Option). Molecular medicine is a specialized area of medicine. Its main thrust is to understand the molecular and cellular basis of disease. Understanding
More information10 th EADO Congress Vilnius, 7-10 May 2014. Ipilimumab update. Michele Maio
10 th EADO Congress Vilnius, 7-10 May 2014 Ipilimumab update Michele Maio Medical Oncology and Immunotherapy, Department of Oncology University Hospital of Siena, Istituto Toscano Tumori SIENA, ITALY Evolving
More informationMutations: 2 general ways to alter DNA. Mutations. What is a mutation? Mutations are rare. Changes in a single DNA base. Change a single DNA base
Mutations Mutations: 2 general ways to alter DNA Change a single DNA base Or entire sections of DNA can move from one place to another What is a mutation? Any change in the nucleotide sequence of DNA Here
More informationIncreasing Innovation in R&D - Seizing early stage external growth opportunities
Increasing Innovation in R&D - Seizing early stage external growth opportunities Paul R. Eynott, PhD sanofi-aventis, US paul.eynott@sanofi-aventis.com -1- Sommaire -2- CHRISTOPHER A. VIEHBACHER Chief Executive
More informationProject ideas of University of Udine for Horizon 2020 Health 2014/2015 www.uniud.it
Project ideas of University of Udine for Horizon 2020 Health 2014/2015 www.uniud.it The University of Udine is an Italian Public University founded in 1978 by National Law No. August 8, 1977 546, art.
More informationDecrease the impact of neurofibromatosis and Schwannomatosis.
Congressiionalllly Diirectted Mediicall Research Programs Neuroffiibromattosiis Research Program (NFRP)) Vision Decrease the impact of neurofibromatosis and Schwannomatosis. Mission Promote research directed
More informationA disease and antibody biology approach to antibody drug discovery
A disease and antibody biology approach to antibody drug discovery Björn Frendéus, PhD VP, Preclinical research Presenter: Björn Frendéus Date: 2011-11-08 1 Antibodies have revolutionized Cancer Treatment!
More informationNIH/NIGMS Trainee Forum: Computational Biology and Medical Informatics at Georgia Tech
ACM-BCB 2015 (Sept. 10 th, 10:00am-12:30pm) NIH/NIGMS Trainee Forum: Computational Biology and Medical Informatics at Georgia Tech Chair: Professor Greg Gibson Georgia Institute of Technology Co-Chair:
More informationRobert Bristow MD PhD FRCPC
Robert Bristow MD PhD FRCPC Clinician-Scientist and Professor, Radiation Oncology and Medical Biophysics, University of Toronto and Ontario Cancer Institute/ (UHN) Head, PMH-CFCRI Prostate Cancer Research
More informationOctober 17, 2005. Elias Zerhouni, M.D. Director National Institutes of Health One Center Drive Suite 126 MSC 0148 Bethesda, MD 20892
October 17, 2005 Elias Zerhouni, M.D. Director National Institutes of Health One Center Drive Suite 126 MSC 0148 Bethesda, MD 20892 Dear Dr. Zerhouni: The undersigned nonprofit medical and scientific societies
More informationProposal to Establish the Crohn s and Colitis Center at the University of Miami Miller School of Medicine
Proposal to Establish the Crohn s and Colitis Center at the University of Miami Miller School of Medicine Contents Mission... 1 Background... 2 Services and Programs... 2 Clinical Care... 2 IBD Specialists...
More informationBreast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns
July 2013 Edition Vol. 7, Issue 7 Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns By Julie Katz, MPH, MPhil Biomarkers played a prominent role in the research presented in
More informationCancer SBL101. James Gomes School of Biological Sciences Indian Institute of Technology Delhi
Cancer SBL101 James Gomes School of Biological Sciences Indian Institute of Technology Delhi All Figures in this Lecture are taken from 1. Molecular biology of the cell / Bruce Alberts et al., 5th ed.
More informationNatalia Taborda Vanegas. Doc. Sci. Student Immunovirology Group Universidad de Antioquia
Pathogenesis of Dengue Natalia Taborda Vanegas Doc. Sci. Student Immunovirology Group Universidad de Antioquia Infection process Epidermis keratinocytes Dermis Archives of Medical Research 36 (2005) 425
More informationMSc in Tissue Engineering One year full-time
Cardiff Institute of Tissue Engineering and Repair (CITER) MSc in Tissue Engineering One year full-time What is Tissue Engineering? "Tissue engineering is an interdisciplinary field combining life and
More informationRoche Position on Human Stem Cells
Roche Position on Human Stem Cells Background Stem cells and treating diseases. Stem cells and their applications offer an enormous potential for the treatment and even the cure of diseases, along with
More informationCancer Services for Adults and Children
UCSF HEALTH Cancer Services for Adults and Children Our world-class clinical and research programs are engaged in the urgent effort to cure cancers and, where cures currently elude us, transform cancer
More informationANIMALS FORM & FUNCTION BODY DEFENSES NONSPECIFIC DEFENSES PHYSICAL BARRIERS PHAGOCYTES. Animals Form & Function Activity #4 page 1
AP BIOLOGY ANIMALS FORM & FUNCTION ACTIVITY #4 NAME DATE HOUR BODY DEFENSES NONSPECIFIC DEFENSES PHYSICAL BARRIERS PHAGOCYTES Animals Form & Function Activity #4 page 1 INFLAMMATORY RESPONSE ANTIMICROBIAL
More information1400 Telegraph Bloomfield Hills, MI 48302 248-334-6877-Phone number/248-334-6877-fax Number CANCER TREATMENT
1400 Telegraph Bloomfield Hills, MI 48302 248-334-6877-Phone number/248-334-6877-fax Number CANCER TREATMENT Learning that your pet has a diagnosis of cancer can be overwhelming. We realize that your pet
More informationAchievements Report CURING CANCER. Of all the questions addressed to CPRIT, the toughest is: When are you going to find a cure for
Achievements Report August 2015 CURING CANCER Of all the questions addressed to CPRIT, the toughest is: When are you going to find a cure for cancer? Since cancer is complex and comes in many forms, its
More informationVUmc Cancer Center Amsterdam / VUmc Institute for Cancer & Immunology CCA/V-ICI
VUmc Cancer Center Amsterdam / VUmc Institute for Cancer & Immunology CCA/V-ICI Annual Report 2006 VUmc Cancer Center Amsterdam / VUmc Institute for Cancer & Immunology CCA/V-ICI Annual Report 2006 Address
More informationMOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015
Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future
More information